文献速递中医内科中药与中成药合理使用

心速宁:基础与临床药理学及中医抗心律失常理论的综述

Xin Su Ning-A Review of Basic and Clinical Pharmacology Integrated With Traditional Chinese Medicine Antiarrhythmic Theory.
PubMed 文献 · Front Pharmacol · 2021-11-11

心速宁是2005年获中国国家食品药品监督管理局批准上市的多组分中成药,源自经典方黄连温胆汤,由11味中药组成。综述汇总其治疗室性心律失常的临床证据(尤其对缺血和病毒性心肌炎所致心律失常有效)及细胞电生理机制(阻滞钠钾通道,兼具I类和III类抗心律失常药特征),并提及一项纳入861例患者的双盲安慰剂对照多中心试验显示其显著抑制室性早搏。

要点

  • 心速宁适用于痰热扰心证心律失常,临床对缺血及病毒性心肌炎相关心律失常尤佳。
  • 细胞电生理显示其延长动作电位时程、抑制振幅,具I类和III类抗心律失常药特征。
  • 861例双盲安慰剂对照多中心试验显示心速宁显著抑制室性早搏。

核心结论

  • 心速宁作为多组分中药抗心律失常药,其临床疗效获传统研究方法的证据支持。

研究设计与样本

  • 综述汇总心速宁的方剂起源、上市前临床使用、药理与临床研究及网络药理学发现。
  • 一项双盲安慰剂对照多中心临床试验纳入861例患者(注册号ChiCTR-TRC-14004180)。

主要发现

  • 心速宁源自黄连温胆汤,由11味中药组成,对痰热扰心证心律失常有效。
  • 临床证据显示对缺血及病毒性心肌炎诱导的心律失常尤其有效,未见明显不良反应报告。
  • 细胞电生理研究显示心速宁延长动作电位时程并抑制振幅,与阻滞钠、钾通道一致。
  • 双盲安慰剂对照多中心试验显示心速宁显著抑制室性早搏(PVC)。

关键数值与推荐

  • 心速宁于2005年获中国国家食品药品监督管理局认证,可制药生产并临床使用。
  • 临床试验纳入861例患者(ChiCTR-TRC-14004180),显示显著抑制室性早搏。

临床怎么用

  • 可依据痰热扰心证辨证使用心速宁治疗室性心律失常。
  • 对缺血性心脏病及病毒性心肌炎相关心律失常可考虑心速宁。

局限性

  • 综述列出了心速宁基础与临床研究的局限性及未来可能的研究方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Xin Su Ning (XSN) is a patented multicomponent medicine, which was certified in 2005 by the China State Food and Drug Administration to be produced pharmaceutically and to be used clinically. The XSN capsule was developed from an effective formula composed by Prof. Shuwen Ding of Shandong University of Traditional Chinese Medicine. Through more than 30 years of clinical observation, Prof. Ding concluded that XSN has a significant effect on arrhythmia with phlegm-heat heart-disturbed syndrome according to the traditional Chinese medicine (TCM) diagnosis. XSN, derived from a classical TCM formula Huanglian Wen Dan Decoction, is formulated with 11 Chinese herbal medicines to treat cardiac ventricular arrhythmia. Clinical evidence suggests that it is particularly efficacious for the arrhythmias induced by cardiac ischemia and viral myocarditis without obvious adverse reactions being reported. Cellular electrophysiological studies in ventricular myocytes revealed that XSN prolongs the duration and suppresses the amplitude of the action potential (AP), which is supported by the blockage of sodium and potassium channels indicating the characteristics of class I and III antiarrhythmic drugs. A recently reported double-blind, placebo-controlled, multicenter clinical trial of XSN enrolled 861 patients (ChiCTR-TRC-14004180) and showed that XSN significantly inhibited premature ventricular contraction (PVC). The cellular electrophysiological discoveries provided the mechanistic evidence for the clinical efficacy on inhibition of PVC by XSN as demonstrated in the clinical trial. These studies, for the first time, provided exclusive evidence that multicomponent TCM antiarrhythmic medicine can be evaluated using conventional research methods that have been used for antiarrhythmic drug discoveries for decades. We aimed to give a comprehensive review on XSN including its origin with the support of TCM theory, its pre-licensing clinical use and development, and its pharmacological and clinical study discoveries. The review will be summarized with the discoveries reported in a novel network pharmacological study that introduced a weight coefficient, which made it possible to evaluate the pharmacological properties of the TCM formula with regard to its formation based on TCM theory. Limitations regarding XSN's basic and clinical research and possible future studies are listed. We hope that the advances in how XSN was studied may offer useful guidance on how other TCM could be studied with respect to the integrity of the TCM formulas.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wang X, Wang T, Ding S, et al. Xin Su Ning-A Review of Basic and Clinical Pharmacology Integrated With Traditional Chinese Medicine Antiarrhythmic Theory. Front Pharmacol. 2021. PMID: 34858163. doi:10.3389/fphar.2021.657484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。